Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein

Table 1 Clinical outcomes for hepatocellular carcinoma patients accompanying portal vein tumor thrombosis following surgical resection

Ref.	PVTT status1	No. of patients	Survival2
			Median (mo)	1-yr (%)	3-yr (%)
Shi et al[49]	Vp2	139	NR	52.1	25.1
	Vp3	169		38.2	17.78
	Vp4	78		24.7	3.6
	Beyond Vp4	20		18.3	0
Lin et al[50]	Vp2
	Vp3	63	NR	52.1	16
	Vp4	5		33.1	0
Chen et al[78]	Vp2-4	88	9	31.1	15.2
Matono et al[79]	Vp3-4	29	16.9	62.1	24.1

¹Beyond Vp4 = extending to superior mesenteric vein;

²Intrahepatic recurred lesions were treated by percutaneous ethanol injection therapy, radiofrequency ablation, transarterial chemoembolization, or systemic chemotherapy based on their hepatic functional reserve and the pattern of intrahepatic recurrence. NR: Not reported; PVTT: Portal vein tumor thrombosis.